ICON will be at #EBF, 18–20 November. Visit booth B-15 to meet our bioanalytical experts and learn how we support drug development with regulatory-compliant solutions. https://ow.ly/L0x150XiU3t
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
LEO Pharma, ICON partner to advance clinical trials in dermatology
This news article, first published on Contract Pharma, covers the strategic partnership between LEO Pharma and ICON to propel clinical trial execution within medical dermatology.
-
Strategies for building greater DE&I in Rare Disease trials
This article describes some of the systemic factors that produce barriers at various stages of the rare disease drug development process, as well as identifies strategies to improve diversity in these trials
-
Optimising biotech trial designs to stretch your cash runway
Brandon Early discusses how optimising trials designs at the earliest stages can help innovative biotech companies to maximise their available capital.
-
As clinical trials face a hiring crunch, here’s how research organisations can pivot
Helen Yeardley, Senior Vice President, Global Clinical Operations, discusses how ICON is adapting to the global shortage of Clinical Research Associates in the industry.
-
The significant increase in demand for Clinical Research Associates (CRAs)
Helen Yeardley, Senior Vice President, Clinical Operations, offers her insights on the role that a Clinical Trial Associate (CRA) plays in the clinical trial process.
-
Pivotal time for CROs': ICON CEO Cutler on changing APAC trial trends
Steve Cutler and Atsushi Ogawa are interviewed in SCRIP where they discuss the increased opportunity for decentralised trials, in addition to the challenges and opportunities for clinical trials in Asia Pacific.
-
Trial blazing
Harpreet Gill, Vice President, Decentralised Clinical Trials at ICON reflects on the progress that has been made in decentralised and hybrid clinical trials in the last number of years in this article in PharmaTimes.
January/February PharmaTimes
-
Historical Controls in Rare Disease drug development: Using RWE to overcome key challenges
The following article will explore the advantages of using HCs, as well as several considerations for their effective use, including scientific methodology and regulatory
-
Fortifying vaccines through disease surveillance and data reporting
In this article, McLendon explores the topic of fortifying vaccines against future pandemics.
-
The power of partnership: Collaborating with patient advocacy organisations for better clinical research
Laura Iliescu explores the powerful potential of collaboration with PAOs for clinical trials, particularly how PAOs can inform trial design and the creation of patient registries.
